BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 8061015)

  • 1. Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies.
    Iberer F; Halwachs-Baumann G; Rödl S; Pleisnitzer A; Wasler A; Auer T; Petutschnigg B; Müller H; Tscheliessnigg K; Wilders-Truschnig M
    J Heart Lung Transplant; 1994; 13(3):405-11. PubMed ID: 8061015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited cytomegalovirus-specific immunoglobulin M and immunoglobulin G profiles in heart transplant recipients.
    Allen MD; Denny CF; Kruse AP; Revkin JH; Fishbein DP; Ashley RL
    J Heart Lung Transplant; 1991; 10(5 Pt 1):664-73. PubMed ID: 1659902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
    Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation.
    Kim CK; Song JH; Kim SM; Peck KR; Oh W; Huh W; Kim YG; Kim SJ; Joh JW; Lee NY; Park CG; Hwang ES; Cha CY; Oh HY
    Transplantation; 2003 Jun; 75(12):2151-5. PubMed ID: 12829929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis and monitoring of active HCMV infection in children with systemic lupus erythematosus.
    Zhang C; Shen K; Jiang Z; He X
    Chin Med J (Engl); 2001 Dec; 114(12):1309-12. PubMed ID: 11793860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
    J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
    Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia.
    Sénéchal M; Dorent R; du Montcel ST; Fillet AM; Ghossoub JJ; Dubois M; Pavie A; Gandjbakhch I
    Clin Transplant; 2003 Oct; 17(5):423-7. PubMed ID: 14703924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Rehak P; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Freigassner M; Prenner G; Hipmair G; Grasser B
    Transpl Int; 1996; 9(3):236-42. PubMed ID: 8723193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.